Piroxicam
| Clinical data | |
|---|---|
| Pronunciation | /paɪˈrɒksɪˌkæm/ |
| Trade names | Feldene, others |
| Other names | Piroksikam, piroxikam |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a684045 |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 99% |
| Metabolism | Liver-mediated hydroxylation and glucuronidation |
| Elimination half-life | 50 hours |
| Excretion | Urine, faeces |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.048.144 |
| Chemical and physical data | |
| Formula | C15H13N3O4S |
| Molar mass | 331.35 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class used to relieve the symptoms of painful inflammatory conditions like arthritis. Piroxicam works by preventing the production of endogenous prostaglandins which are involved in the mediation of pain, stiffness, tenderness and swelling. The medicine is available as capsules, tablets and, in some countries, as a prescription-free gel 0.5%. It is also available in a betadex formulation, which allows a more rapid absorption of piroxicam from the digestive tract. Piroxicam is one of the few NSAIDs that can be given parenteral routes.
It was patented in 1968 by Pfizer and approved for medical use in 1979. It became generic in 1992, and is marketed worldwide under many brand names.